Drugs / YQ23
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04513067 | Aug 2020 → Jul 2023 | neoplasm | New Beta Innovation Limited | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04792008 | Mar 2021 → Aug 2023 | limb ischemia | New Beta Innovation Limited | Terminated | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03802292 Comparator | Jan 2019 → Sep 2020 | — | New Beta Innovation Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YQ23 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04513067 ↗ |
| Route | Intravenous | “delivered via intravenous route” NCT03802292 ↗ |